USSN: 10/088,632 Group Art Unit: 1648

AMENDMENTS TO THE CLAIMS

- 26. (Previously presented) A monovalent influenza vaccine composition comprising an influenza virus component which is a low dose of egg-derived influenza virus antigen from an influenza virus strain that is associated with a pandemic outbreak, or has the potential to be associated with a pandemic outbreak, in combination with a suitable adjuvant, wherein the low antigen dose is less than 15 μg of haemagglutinin per dose or no more than 15 μg per combined dose of vaccine.
- 27. (Previously presented) A vaccine composition according to claim 26 wherein the influenza virus antigen is in the form of purified whole influenza virus.
- 28. (Previously presented) A vaccine composition according to claim 26 where the adjuvant is an aluminium salt or salts.
- 29. (Previously presented) A vaccine composition according to claim 28 wherein the adjuvant is aluminium hydroxide and aluminium phosphate.
- 30. (Previously presented) A vaccine composition according to claim 29 wherein the amount of aluminium phosphate exceeds the amount of aluminium hydroxide.
- 31. (Currently amended) A vaccine composition according to claim 28 wherein the aluminium salts are present in the range 0.4 to 1.0 $[[\mu g]]$ mg per vaccine dose.
- 32. (Previously presented) A vaccine composition according to claim 26 in which the low antigen dose is less than 10 µg of haemagglutinin per dose or per combined dose of vaccine.
- 33. (Previously presented) A vaccine composition according to claim 32 in which the antigen dose is between 0.1 μ g and 7.5 μ g or between 1 and 5 μ g of haemagglutinin per dose or per combined dose of vaccine.
- 34. (Previously presented) A vaccine composition according to claim 26 wherein the influenza virus antigen is substantially free of host cell contamination.

USSN: 10/088,632 Group Art Unit: 1648

35. (Previously presented) A vaccine composition according to claim 26 wherein the influenza virus component is purified by a method which includes a protease incubation step to digest non-influenza virus proteins.

36-40. (Canceled)

- 41. (Previously presented) A method for the production of an influenza vaccine for a pandemic situation which method comprises admixing egg-derived influenza virus antigen from a single influenza virus strain that is associated with a pandemic outbreak or has the potential to be associated with a pandemic outbreak, with a suitable adjuvant and providing vaccines lots or vaccine kits which contain less than 10 µg influenza haemagglutinin antigen per dose or no more than 15 µg haemagglutinin per combined dose.
- 42. (Previously presented) A method according to claim 41 wherein the antigen is highly purified.
- 43. (Previously presented) A method according to claim 41 wherein the influenza virus antigen is in the form of whole influenza virus particles.
- 44. (Previously presented) The vaccine composition of claim 26 wherein the antigen is selected from an H2 antigen such as H2N2 and an H5 antigen such as H5N1.
- 45. (Canceled)
- 46. (Previously presented) The method of claim 41 wherein the antigen is selected from an H2 antigen such as H2N2 and an H5 antigen such as H5N1.

47-50. (Canceled)